Advancing cancer prevention and early detection through real-time molecular insight.
miRoncol was founded with a clear vision: to make meaningful early cancer risk assessment accessible to individuals and healthcare professionals who value prevention and early detection.
Our Real-time Multi-Cancer Early Risk Assessment uses microRNA biomarkers and AI-based analysis to detect biological signals consistent with early cancer providing a new layer of clarity in cancer prevention and early detection.
Our Purpose
Empower Individuals
To take proactive steps in their health journey.
Support Healthcare Providers
With science-backed tools that complement clinical practice.
Advance Cancer Prevention
By bringing real-time molecular insights into everyday health checkups.
Our People
Behind miRoncol is a multidisciplinary team of leaders in oncology, molecular biology, data science, and health innovation. Together, we are committed to turning cutting-edge research into tools that are accurate, affordable, and accessible.
Our Scientific Integrity
Scientific rigor is at the core of what we do. Our approach is built on:
- Studies using 11,000+ human samples across more than a dozen cancers
- Specificity above 99% and high sensitivity for many common solid tumours
- Publications in Cancers (2022) and Scientific Reports (2024)
- Guidance from an internationally recognized Scientific Advisory Board
Our Principles
- Prevention-first — designed for healthy, proactive individuals
- Ethical & responsible — complements, not replaces, physician-led care
- Scientifically transparent — grounded in peer-reviewed research
- Accessible — aiming to expand prevention and early detection tools beyond existing options
Next Step
Learn more about who we are and why we’re committed to transforming cancer prevention.
